Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Eltoprazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.56 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.56 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.56 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eltoprazine SCHEMBL29438749 | 1.00 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL31235563 | 1.00 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL9466563 | 1.00 | ADRB1 (0.97) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL177715 | 0.98 | ADRB1 (1.00) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL1651102 | 0.95 | ADRB1 (0.94) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL5253570 | 0.94 | ADRB1 (0.85) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL5246531 | 0.94 | ADRB1 (0.85) | ADRB1DRD2DRD1HTR2ADRD3 | |
| SCHEMBL4243350 | 0.92 | ADRB1 (0.88) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Eltoprazine SCHEMBL27615104 | 0.89 | ADRB1 (0.81) | ADRB1DRD2DRD1HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL12478620 | 0.87 | ADRB1 (0.74) | ADRB1DRD2DRD1HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067244-A1 | Treatment for Neurological and Mental Disorders | PSYCHOGENICS INC (US) | 2016-03-10 | — | — | US | claimed |
| US-20120190690-A1 | ELTOPRAZINE FOR THE TREATMENT OF WEIGHT DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-26 | — | — | US | claimed |
| US-20120136005-A1 | ELTOPRAZINE FOR THE TREATMENT OF ANXIETY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-05-31 | — | — | US | claimed |
| EP-2448579-A1 | ELTOPRAZINE FOR THE TREATMENT OF WEIGHT DISORDERS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-05-09 | — | — | EP | claimed |
| EP-2448580-A1 | ELTOPRAZINE FOR THE TREATMENT OF ANXIETY | Merz Pharma GmbH & Co. KGaA (DE) | 2012-05-09 | — | — | EP | claimed |
| US-20110288105-A1 | ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-11-24 | — | — | US | claimed |
| EP-2373314-A1 | USE OF ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA | Merz Pharma GmbH & Co. KGaA (DE) | 2011-10-12 | — | — | EP | claimed |
| US-20110183995-A1 | ELTOPRAZINE FOR SUPPRESSION OF L-DOPA INDUCED DYSKINESIAS | NEUROSEARCH A/S (DK) | 2011-07-28 | — | — | US | claimed |
| EP-2317996-A1 | ELTOPRAZINE FOR SUPPRESSION OF L-DOPA INDUCED DYSKINESIAS | Björklund, Anders (SE) | 2011-05-11 | — | — | EP | claimed |
| WO-2011000565-A1 | ELTOPRAZINE FOR THE TREATMENT OF ANXIETY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | WO | claimed |
| WO-2011000564-A1 | ELTOPRAZINE FOR THE TREATMENT OF DRUG ADDICTION | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | WO | claimed |
| WO-2011000562-A1 | ELTOPRAZINE FOR THE TREATMENT OF CERTAIN MOVEMENT DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | WO | claimed |
| WO-2011000563-A1 | ELTOPRAZINE FOR THE TREATMENT OF WEIGHT DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | WO | claimed |
| WO-2010063486-A1 | USE OF ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | claimed |
| EP-2193794-A1 | Use of eltoprazine for the treatment of L-Dopa-induced dyskinesia | Merz Pharma GmbH & Co. KGaA (DE) | 2010-06-09 | — | — | EP | claimed |
| WO-2009156380-A1 | ELTOPRAZINE FOR SUPPRESSION OF L-DOPA INDUCED DYSKINESIAS | BJOERKLUND ANDERS (SE) | 2009-12-30 | — | — | WO | claimed |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240159774-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-16 | — | — | US | disclosed |
| US-6090812-A | THERAPY FOR PSYCHOLOGICAL, CENTRAL NERVOUS SYSTEM DISORDERS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2000-07-18 | — | — | US | disclosed |
| EP-0908458-A1 | Substituted pyridylmethylpiperazine and -piperidine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183995-A1 | ELTOPRAZINE FOR SUPPRESSION OF L-DOPA INDUCED DYSKINESIAS | PRLHR, PARK7, COMT | ADRB1 150/4885DRD2 77/4885DRD1 145/4885 |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | CASR, ORAI1, TRPC3 | ADRB1 852/4885DRD2 383/4885DRD1 743/4885 |
| US-20160067244-A1 | Treatment for Neurological and Mental Disorders | PNMT, COMT, ACHE | ADRB1 147/4885DRD2 87/4885DRD1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.